Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption

Lei Xiong, Ji Ung Jung, Haitao Wu, Wen Fang Xia, Jin Xiu Pan, Chengyong Shen, Lin Mei, Wencheng Xiong

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Bone mass is maintained by balanced activity of osteoblasts and osteoclasts. Lrp4 (low-density lipoprotein receptor related protein 4) is a member of the LDL receptor family, whose mutations have been identified in patients with high-bone-mass disorders, such as sclerosteosis and van Buchem diseases. However, it remains unknown whether and how Lrp4 regulates bone-mass homeostasis in vivo. Here we provide evidence that Lrp4-null mutation or specific mutation in osteoblast-lineage cells increased cortical and trabecular bone mass, which was associated with elevated bone formation and impaired bone resorption. This phenotype was not observed in osteoclast-selective Lrp4 knockout mice. Mechanistic studies indicate that loss of Lrp4 function in osteoblast-lineage cells increased serum levels of sclerostin, a key factor for bone-mass homeostasis that interacts with Lrp4, but abolished the inhibition of Wnt/β-catenin signaling and osteoblastic differentiation by sclerostin. Concomitantly, sclerostin induction of RANKL (receptor activator of nuclear kappa B ligand) was impaired, leading to a lower ratio of RANKL over OPG (osteoprotegerin) (a key factor for osteoclastogenesis). Taken together, these results support the view for Lrp4 as a receptor of sclerostin to inhibit Wnt/β-catenin signaling and bone formation and identify Lrp4 as a critical player in bonemass homeostasis.

Original languageEnglish (US)
Pages (from-to)3487-3492
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume112
Issue number11
DOIs
StatePublished - Mar 17 2015

Fingerprint

LDL-Receptor Related Proteins
LDL Receptors
Bone Resorption
Osteoblasts
Osteogenesis
Bone and Bones
Catenins
Homeostasis
Osteoclasts
Cytoplasmic and Nuclear Receptors
Mutation
Osteochondrodysplasias
RANK Ligand
Knockout Mice
Ligands
Phenotype

Keywords

  • LRP4
  • Osteoblasts
  • Osteoclasts
  • Sclerostin
  • β-catenin

ASJC Scopus subject areas

  • General

Cite this

Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption. / Xiong, Lei; Jung, Ji Ung; Wu, Haitao; Xia, Wen Fang; Pan, Jin Xiu; Shen, Chengyong; Mei, Lin; Xiong, Wencheng.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 11, 17.03.2015, p. 3487-3492.

Research output: Contribution to journalArticle

Xiong, Lei ; Jung, Ji Ung ; Wu, Haitao ; Xia, Wen Fang ; Pan, Jin Xiu ; Shen, Chengyong ; Mei, Lin ; Xiong, Wencheng. / Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption. In: Proceedings of the National Academy of Sciences of the United States of America. 2015 ; Vol. 112, No. 11. pp. 3487-3492.
@article{b11361e7716d4c1a974db0f55479bada,
title = "Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption",
abstract = "Bone mass is maintained by balanced activity of osteoblasts and osteoclasts. Lrp4 (low-density lipoprotein receptor related protein 4) is a member of the LDL receptor family, whose mutations have been identified in patients with high-bone-mass disorders, such as sclerosteosis and van Buchem diseases. However, it remains unknown whether and how Lrp4 regulates bone-mass homeostasis in vivo. Here we provide evidence that Lrp4-null mutation or specific mutation in osteoblast-lineage cells increased cortical and trabecular bone mass, which was associated with elevated bone formation and impaired bone resorption. This phenotype was not observed in osteoclast-selective Lrp4 knockout mice. Mechanistic studies indicate that loss of Lrp4 function in osteoblast-lineage cells increased serum levels of sclerostin, a key factor for bone-mass homeostasis that interacts with Lrp4, but abolished the inhibition of Wnt/β-catenin signaling and osteoblastic differentiation by sclerostin. Concomitantly, sclerostin induction of RANKL (receptor activator of nuclear kappa B ligand) was impaired, leading to a lower ratio of RANKL over OPG (osteoprotegerin) (a key factor for osteoclastogenesis). Taken together, these results support the view for Lrp4 as a receptor of sclerostin to inhibit Wnt/β-catenin signaling and bone formation and identify Lrp4 as a critical player in bonemass homeostasis.",
keywords = "LRP4, Osteoblasts, Osteoclasts, Sclerostin, β-catenin",
author = "Lei Xiong and Jung, {Ji Ung} and Haitao Wu and Xia, {Wen Fang} and Pan, {Jin Xiu} and Chengyong Shen and Lin Mei and Wencheng Xiong",
year = "2015",
month = "3",
day = "17",
doi = "10.1073/pnas.1419714112",
language = "English (US)",
volume = "112",
pages = "3487--3492",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "11",

}

TY - JOUR

T1 - Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption

AU - Xiong, Lei

AU - Jung, Ji Ung

AU - Wu, Haitao

AU - Xia, Wen Fang

AU - Pan, Jin Xiu

AU - Shen, Chengyong

AU - Mei, Lin

AU - Xiong, Wencheng

PY - 2015/3/17

Y1 - 2015/3/17

N2 - Bone mass is maintained by balanced activity of osteoblasts and osteoclasts. Lrp4 (low-density lipoprotein receptor related protein 4) is a member of the LDL receptor family, whose mutations have been identified in patients with high-bone-mass disorders, such as sclerosteosis and van Buchem diseases. However, it remains unknown whether and how Lrp4 regulates bone-mass homeostasis in vivo. Here we provide evidence that Lrp4-null mutation or specific mutation in osteoblast-lineage cells increased cortical and trabecular bone mass, which was associated with elevated bone formation and impaired bone resorption. This phenotype was not observed in osteoclast-selective Lrp4 knockout mice. Mechanistic studies indicate that loss of Lrp4 function in osteoblast-lineage cells increased serum levels of sclerostin, a key factor for bone-mass homeostasis that interacts with Lrp4, but abolished the inhibition of Wnt/β-catenin signaling and osteoblastic differentiation by sclerostin. Concomitantly, sclerostin induction of RANKL (receptor activator of nuclear kappa B ligand) was impaired, leading to a lower ratio of RANKL over OPG (osteoprotegerin) (a key factor for osteoclastogenesis). Taken together, these results support the view for Lrp4 as a receptor of sclerostin to inhibit Wnt/β-catenin signaling and bone formation and identify Lrp4 as a critical player in bonemass homeostasis.

AB - Bone mass is maintained by balanced activity of osteoblasts and osteoclasts. Lrp4 (low-density lipoprotein receptor related protein 4) is a member of the LDL receptor family, whose mutations have been identified in patients with high-bone-mass disorders, such as sclerosteosis and van Buchem diseases. However, it remains unknown whether and how Lrp4 regulates bone-mass homeostasis in vivo. Here we provide evidence that Lrp4-null mutation or specific mutation in osteoblast-lineage cells increased cortical and trabecular bone mass, which was associated with elevated bone formation and impaired bone resorption. This phenotype was not observed in osteoclast-selective Lrp4 knockout mice. Mechanistic studies indicate that loss of Lrp4 function in osteoblast-lineage cells increased serum levels of sclerostin, a key factor for bone-mass homeostasis that interacts with Lrp4, but abolished the inhibition of Wnt/β-catenin signaling and osteoblastic differentiation by sclerostin. Concomitantly, sclerostin induction of RANKL (receptor activator of nuclear kappa B ligand) was impaired, leading to a lower ratio of RANKL over OPG (osteoprotegerin) (a key factor for osteoclastogenesis). Taken together, these results support the view for Lrp4 as a receptor of sclerostin to inhibit Wnt/β-catenin signaling and bone formation and identify Lrp4 as a critical player in bonemass homeostasis.

KW - LRP4

KW - Osteoblasts

KW - Osteoclasts

KW - Sclerostin

KW - β-catenin

UR - http://www.scopus.com/inward/record.url?scp=84925337156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925337156&partnerID=8YFLogxK

U2 - 10.1073/pnas.1419714112

DO - 10.1073/pnas.1419714112

M3 - Article

C2 - 25733894

AN - SCOPUS:84925337156

VL - 112

SP - 3487

EP - 3492

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 11

ER -